Second Genome, a South San Francisco, California-based biopharmaceutical company, raised $8.4m in Series B financing.
SR One made – the corporate venture capital arm of GlaxoSmithKline – the investment, which brought the total Series B funding round to $51m. It joined Pfizer Venture Investments, Roche Venture Fund, and Digitalis Ventures. In conjunction with the funding, Jill Carroll of SR One joined Second Genome’s board of directors.
The company intends to use the funds to accelerate the translation of its microbiome discoveries into a pipeline of clinical opportunities.
Led by newly appointed Glenn Nedwin, Ph.D., CEO president and member of the board of directors, Karim Dabbagh, Ph.D., CSO, and Corey Goodman, Ph.D., chairman and co-founder, Second Genome advances novel medicines developed through a drug discovery platform that integrates microbiome and host biology for the identification of novel targets and drugs. Its data analysis techniques enable the identification of microbes and microbial biomarkers that influence a given disease state. Combined with expertise in drug development, the company’s team has built the foundation for rapid discovery of new therapeutic options for patients in a numerous microbiome-related diseases.